NEXGEL (NXGL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 May, 2026Executive summary
The annual meeting is scheduled for July 10, 2026, with seven key proposals for shareholder action, including director elections, approval of significant stock issuances, reincorporation, capital structure changes, executive compensation, and auditor ratification.
Shareholders can vote in person, by mail, phone, or online, and the board recommends voting in favor of all proposals.
Proxy materials, including the annual report and proxy statement, are available online and by mail.
Voting matters and shareholder proposals
Seven proposals: election of seven directors, approval of stock issuance exceeding 19.99% of outstanding shares, reincorporation from Delaware to Nevada, increase in authorized shares, discretionary reverse stock split, advisory vote on executive compensation, and auditor ratification.
Proposals 4 and 5 serve as Delaware-law fallbacks if reincorporation is not approved.
Board unanimously recommends voting FOR all proposals.
Shareholders may submit proposals for the 2027 annual meeting per SEC rules and company bylaws.
Board of directors and corporate governance
Seven director nominees, including experienced professionals in finance, biotech, and business leadership.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent directors.
Board leadership is separated between the Chairperson and CEO roles.
Code of Business Conduct and Ethics, insider trading, and hedging policies are in place.
Latest events from NEXGEL
- Expanded regenerative medicine portfolio and direct sales force set stage for rapid growth.NXGL
Planet MicroCap Las Vegas 202617 Jun 2026 - Shareholders will vote on director elections, share issuances, reincorporation, and key governance changes.NXGL
Proxy filing9 Jun 2026 - Major acquisition expected to triple annual revenue and improve profitability.NXGL
Q1 202615 May 2026 - Revenue up 31.5% to $11.4M, but net loss of $3.0M and going concern risks persist.NXGL
Q4 202523 Apr 2026 - Acquisition and partnership triple revenue, drive profitability, and expand into regenerative medicine.NXGL
M&A announcement21 Apr 2026 - Hydrogel innovation and strategic partnerships fuel rapid growth and expanding product lines.NXGL
Planet MicroCap Showcase: VEGAS 20253 Feb 2026 - Record Q2 revenue and strong outlook driven by branded products and Silly George growth.NXGL
Q2 20242 Feb 2026 - Q3 revenue up 141% to $2.94M, gross margin 43.6%, but losses and risks persist.NXGL
Q3 202414 Jan 2026 - Strong growth from product innovation, acquisitions, and major partnerships, with profitability in focus.NXGL
IAccess Alpha–Buyside Best Ideas Winter Virtual Conference 202411 Jan 2026